A promising first Convergence in Oncology Summit

Convergence in Oncology is a unique opportunity in the quest to fight cancer. Focusing on Prevention & Diagnostics, Therapy, and Digitization, the forthcoming Summit at Biopôle Lausanne will offer attendees many opportunities to network and explore synergies.

From diagnostics to therapeutics, rapid change in technology innovation modifies the landscape faster than any organizations can keep up with. Convergence of technologies from mature and emerging sectors are creating new opportunities that can significantly accelerate disruptive solutions that benefit patients globally.

The principal aim of the Convergence in Oncology Summit, an annual event organized by professionals for professionals, is to promote development of new solutions through convergence and sharing of opportunities in the field of Oncology.

Major players expected 

As Emanuela Jurietti, Biopôle’s Marketing & Communications Manager explains, the Summit is organized in several consecutive sessions led by a panel of industry leaders bringing their perspective to the topic, followed by several presentations by leading company CEOs covering innovative emerging and disrupting solutions relevant to the panel discussion. 

The first panelists announced are promising with Professor George Coukos from the Ludwig Research Institute and Jurgi Camblong, Sophia Genetics CEO. Major industry leaders will also be present with companies like Roche, Glenmark and IBM. 

Engaging panels to learn faster 

The Summit is organized around four panel sessions, the final panel exploring lessons learned and synergies across topics covered during the Summit. The first panel will be on “Digitalization at the service of Oncology; From Prevention to Monitoring”, the second will be about “Innovation in Prevention & Diagnostics” and the third “Innovation in Therapeutics”. 

What makes this format particularly engaging for professionals is its organization . Moderated by an expert, each panel session will have approximately 8 persons on stage, investors and members of academia on one side, corporates coming from experienced startups and bigger, established players on the other. Led by Tania Dussey-Cavassini, the 4th panel discussion will be the opportunity to go through the lessons learnt during the afternoon, before starting the evening networking program. 

Life science start-ups interested to participate can learn more about this event  and register on the Summit’s website. 

(ES)